ID: ALA2230211

Max Phase: Preclinical

Molecular Formula: C18H20ClN3O4S2

Molecular Weight: 441.96

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCOC(=O)CSc1nc2cc(-n3nc(C(C)(C)C)oc3=O)c(Cl)cc2s1

Standard InChI:  InChI=1S/C18H20ClN3O4S2/c1-5-6-25-14(23)9-27-16-20-11-8-12(10(19)7-13(11)28-16)22-17(24)26-15(21-22)18(2,3)4/h7-8H,5-6,9H2,1-4H3

Standard InChI Key:  KHHGZSWLDAPGDU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 441.96

Molecular Weight (Monoisotopic): 441.0584

AlogP: 4.43

#Rotatable Bonds: 6

Polar Surface Area: 87.22

Molecular Species: NEUTRAL

HBA: 9

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.44

CX LogP: 5.74

CX LogD: 5.74

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.41

Np Likeness Score: -1.73

References

1. Jiang LL, Tan Y, Zhu XL, Wang ZF, Zuo Y, Chen Q, Xi Z, Yang GF..  (2010)  Design, synthesis, and 3D-QSAR analysis of novel 1,3,4-oxadiazol-2(3H)-ones as protoporphyrinogen oxidase inhibitors.,  58  (5): [PMID:19954223] [10.1021/jf9026298]

Source

Source(1):

• Scientific Literature